

To,
Head, Listing Compliance Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

Scrip Code: 542650

To,
Head, Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra – Kurla Complex, Bandra (East),
Mumbai – 400 051

Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

‘Metropolis’ Core-Revenue Growth (Excl. Covid & Covid Allied, PPP Contract & Hi-Tech) at Rs. 245 crs in Q4FY23; up by 15% YoY’

You are requested to take the above information on record.

Thanking you,

Yours faithfully

For **Metropolis Healthcare Limited**

Rakesh Agarwal
Chief Financial Officer

Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis' Core-Revenue Growth (Excl. Covid & Covid Allied, PPP Contract & Hi-Tech) at Rs. 245 crs in Q4FY23; up by 15% YoY

Total B2C Revenue in Focus Cities grew by 17% YoY in Q4FY23 & 20% in FY23

Q4FY23 & FY23 Key Highlights

- **Core Business[#] Revenue** (Excl. Covid & Covid Allied, PPP Contract & Hi-tech) growth stood at **15% for Q4FY23 & 15% for FY23** on Y-o-Y basis
- **Core Business Volume growth** for Q4FY23 stood at **15% & 13% for FY23** on Y-o-Y basis
- **EBIDTA*** before Network Expansion for **Q4FY23 stood 26.9%**
- **Premium Wellness** segments **grew by 43% for Q4 FY23 & by 45% for FY23** indicating strong Brand Equity Consumer's Trust on Metropolis Brand. Contribution of premium wellness stood at **15% of the non-covid revenues**
- Non-Covid Revenue from **North grew by ~30% for Q4FY23** on Y-o-Y basis
- B2C revenue growth for Q4FY23 in **Mumbai grew by 18% & Pune grew 23%** on account of our strong brand presence & dense network
- B2C revenue for Q4FY23 in **other cities grew by 30%** indicating our strong execution & penetration in the newer geographies

*EBIDTA before CSR & ESOP (25.7%) + dilution on account of Network Expansion (1.2%)

[#]Core Business – Exclude revenue from Covid & Covid Allied, PPP Contracts & Hi-tech

Mumbai, May 16, 2023: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the fourth quarter of financial year 2023.

Q4FY23 Financial Highlights

Core Business Revenue

Rs. 245 Crs.

Up by 15% YOY

EBIDTA Margin (before CSR & ESOP)

25.7%

Profit after Tax

Rs. 33.5 Crs.

“Our Core business revenue grew by 15% for Q4FY23 & FY23 on Y-o-Y basis. We have been witnessing continuous uptick in our core business revenues over the last 4 quarters with volumes growing across markets. Our revenues from North grew by ~30% for Q4FY23 strengthening our presence in non-core geographies & expanding our reach on Pan-India basis.

Revenue contribution from our premium wellness segment increased to 15% in Q4FY23 & witnessed a healthy growth of 43% Y-o-Y, a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers.

Going forward, we focus on our network expansion, growing our specialised & wellness segments and upgrading our IT infrastructure for enhancing the consumer experience.

We believe Metropolis is rightly placed to attain higher market share across geographies & outperform the industry growth.

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

ACCREDITATIONS FOR METROPOLIS

Our MD Ms. Ameera Shah honoured with the **Most Powerful Woman in Business Award** by Business Today and also has been recognized as the “Most Influential Women in Healthcare” by Business World.

Our CFO Mr. Rakesh Agarwal honored with the **Top 100 CFO Award** for his excellent and outstanding Strategy Execution at the CFO100 Programme.

Metropolis bagged the “**Best Organization for Women Empowerment**” Award and our CHRO Ms. Ishita Medhekar won the “**Woman Leader of the Organization**” Award at the 4th Edition of Women Empowerment Summit and GIWL (Great Indian Women Leadership) Awards by UBS Forums

Metropolis Labs in Ghana won the Overall Best Pathology Laboratory Centre of the Year Award at the Ghana Medical Laboratories Excellence Awards (GMLEA).

Metropolis honoured with the **Great Place to Work For**” certification for building and sustaining a high trust, high Performance culture.

Metropolis Healthcare’s Annual Report 2021-22 won the “**Gold**” Award at the Vision Awards 2021/22 Annual Reports Competition by LACP League of American Professionals

MHL’s Procurement Team won the **Top Function Award in the Healthcare category** by the Institute of Supply Chain and Management and **Top 200 Supply Chain Award** by Alden Global Advisers.

Our Chairman Dr. Sushil Shah recognized with the **Hurun Industry Achievement Award 2022** at the 10th edition of Most Respected Entrepreneurs Awards, organized by Hurun India.

Metropolis Healthcare won the **Gold Award for Excellence in High end Diagnostics** and **Silver Award for Excellence in Pathology Services** at the 8th India Health and Wellness Awards by IHW Council.

Metropolis Healthcare’s subsidiary Hitech Diagnostic Centre Pvt Limited honoured with the **Best Standalone Regional Laboratory Chain South** at the ET Healthcare Excellence Awards 2022.

In INR Crs.	Q4FY23	Q4FY22	FY23	FY22
Revenue from Operations	282.5	305.9	1,148.2	1,228.3
Core Business Revenue	244.7	213.2	949.2	824.3
EBIDTA (before CSR & ESOP)	72.5	82.2	304.4	361.6
EBIDTA margin (before CSR & ESOP)	25.7%	26.9%	26.5%	29.4%
Profit After Tax	33.5	40.1	143.4	214.7
PAT Margin (%)	11.9%	13.1%	12.5%	17.5%

About Metropolis: Established in 1981, Metropolis Healthcare Limited is a leading diagnostics company in India with a widespread presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company is empowered with a robust network of over 175 labs, 3,675 collection centres and 10,000+ touch points. Metropolis’ commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#).

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head - Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff

+91 77383 77756 / +91 98205 19303

shogun.jain@sgapl.net / sagar.shroff@sgapl.net